IDXXIDEXX Laboratories, Inc.
AI adoption · Q1 2026 earnings call
Health CareScaling
6
extracted from this call
3 / 5
operational, no hard numbers
Not disclosed
no breakout in this call
Incoming CEO Mike Erickson identified AI as a named strategic priority, citing existing AI capabilities embedded in inVue Dx and ezyVet software, and signaling intent to expand AI's role in innovation, testing access, and patient-level insights. The most concrete AI product discussed was the F&A (fine needle aspirate) application on the inVue Dx platform, which uses AI analysis for cytology/mast cell tumor detection. Management committed to sharing more detail on AI strategy at an August 2026 Investor Day. AI commentary was largely directional and aspirational, with limited quantification.
Adopter
See full leaderboard →53/ 100
76
stage: scaling · max spec: 3
40
1 quant outcome
35
1 scope
product_embedded
6 AI mentions from this call.
Extracted verbatim from the IDXX Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T3Q&A· CEO· Product-embedded AIAnd then just on F&A again. And just on kind of the building a broader launch there.
“we know that 90% or more of the masses that come in actually don't get investigated because it just takes a lot of work to do it manually with cytology. And frankly, it's pretty expensive. And so we're really excited about F&A on inVue Dx as an opportunity to not only elevate the standard of care, but also expand access to muted care and we see a long runway for doing that.”
— Michael Erickson, IDXX earnings callinVue Dx, F&A - T3Q&A· CEO· Product-embedded AImaybe just two for me. First on ex U.S. dynamics... And then maybe the second one for me is just coming back to inVue and the F&A rollout.
“F&A, as Jay mentioned, it's really a very exciting platform within a platform, not just what it can do on the instrument with AI and detection of mast cell tumor cells, but also the one-click workflow if a customer wants added interpretation from an IDEXX board-certified pathologists.”
— Michael Erickson, IDXX earnings callinVue Dx, F&A - T3Prepared remarks· CEO· Product-embedded AI
“Practices are seeing the value of evaluating lumps and bumps during the patient visit with rapid cytology insights supported by AI analysis and optional expert pathologists review available with a single click.”
— Jay Mazelsky, IDXX earnings callinVue Dx, F&A - T3Prepared remarks· CEO· Product-embedded AI
“combining high definition AI-powered imaging with up to 60% lower dose than premium competitors.”
— Jay Mazelsky, IDXX earnings callImageVue DR50 PLUS - T2Prepared remarks· CEO· Product-embedded AI
“Another priority for us is AI. We have a well-established AI capability at IDEXX with AI embedded in platforms such as inVue Dx and our ezyVet software. Looking forward, I see advancements in AI as incredibly promising to further accelerate our innovation, expand testing access and utilization and drive deeper patient level insights. I plan to share more on this at our upcoming August Investor Day.”
— Michael Erickson, IDXX earnings callinVue Dx, ezyVet - T2Q&A· CEO· Product-embedded AIwhat is your expectation? Or when should we hear more on the next menu expansion for inVue and how meaningful full that could be to the platform?
“As Jay shared and as I shared previously at our Investor Days, we see 100 million cytologies, beyond what we're talking about already around the world. And so we see a long road map, a very exciting road map ahead on inVue Dx and we'll continue to share more about that as we move forward.”
— Michael Erickson, IDXX earnings callinVue Dx
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of AI-related revenue contribution or ARR from any AI-enabled product.
- No capex or R&D spend attributed specifically to AI development.
- No adoption metrics (e.g., number of practices using AI features) disclosed for ezyVet AI or inVue Dx AI specifically.
- Incoming CEO stated AI strategy details would be shared at August 2026 Investor Day — no analyst pressed for more specifics on the call.
- F&A utilization described as 'tracking to planning assumptions' but no specific utilization rates or revenue per instrument attributable to F&A/AI were disclosed.
- No competitive AI landscape commentary provided.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.